BR112023021257A2 - Métodos para a administração combinada de deutetrabenzina e um cyp2d6 - Google Patents

Métodos para a administração combinada de deutetrabenzina e um cyp2d6

Info

Publication number
BR112023021257A2
BR112023021257A2 BR112023021257A BR112023021257A BR112023021257A2 BR 112023021257 A2 BR112023021257 A2 BR 112023021257A2 BR 112023021257 A BR112023021257 A BR 112023021257A BR 112023021257 A BR112023021257 A BR 112023021257A BR 112023021257 A2 BR112023021257 A2 BR 112023021257A2
Authority
BR
Brazil
Prior art keywords
cyp2d6
deutetrabenzine
methods
combined administration
patient
Prior art date
Application number
BR112023021257A
Other languages
English (en)
Inventor
Gordon Loewen
Satjit Brar
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of BR112023021257A2 publication Critical patent/BR112023021257A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

métodos para a administração combinada de deutetrabenzina e um cyp2d6. a presente invenção refere-se a um método para tratar uma doença ou distúrbio neurológico ou psiquiátrico em um paciente em necessidade do mesmo, compreendendo: administrar um inibidor do transportador vesicular de monoamina 2 (vmat2) ao paciente em necessidade do mesmo, sendo também administrado ao paciente um forte inibidor de citocromo p450 2d6 (cyp2d6).
BR112023021257A 2021-04-15 2022-04-14 Métodos para a administração combinada de deutetrabenzina e um cyp2d6 BR112023021257A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163175378P 2021-04-15 2021-04-15
US202163189939P 2021-05-18 2021-05-18
US202163238500P 2021-08-30 2021-08-30
PCT/US2022/024840 WO2022221546A1 (en) 2021-04-15 2022-04-14 Methods for the combined administration of deutetrabenazine and a cyp2d6 inhibitor

Publications (1)

Publication Number Publication Date
BR112023021257A2 true BR112023021257A2 (pt) 2023-12-12

Family

ID=81581216

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021257A BR112023021257A2 (pt) 2021-04-15 2022-04-14 Métodos para a administração combinada de deutetrabenzina e um cyp2d6

Country Status (6)

Country Link
US (1) US20240207247A1 (pt)
EP (1) EP4322934A1 (pt)
JP (1) JP2024514873A (pt)
BR (1) BR112023021257A2 (pt)
IL (1) IL307680A (pt)
WO (1) WO2022221546A1 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CN107624067A (zh) * 2015-03-06 2018-01-23 奥斯拜客斯制药有限公司 用于治疗异常不自主运动障碍的方法
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Also Published As

Publication number Publication date
US20240207247A1 (en) 2024-06-27
JP2024514873A (ja) 2024-04-03
IL307680A (en) 2023-12-01
WO2022221546A1 (en) 2022-10-20
EP4322934A1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
Chi Complications caused by nitrous oxide in dental sedation
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
NO20045056L (no) Fremgangsmater for behandling av hepatitt
AR043188A1 (es) Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
MX2010003556A (es) Regimen de tratamiento para trastornos proliferantes.
EA200401366A1 (ru) Способы лечения некротизирующего энтероколита
BR112023021131A2 (pt) Tratamento de tremor essencial
BR112023002458A2 (pt) Métodos de tratamento da gota
CR20240043A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
BR112023021257A2 (pt) Métodos para a administração combinada de deutetrabenzina e um cyp2d6
MX2022014199A (es) Usos y formulaciones de los cannabinoides.
Kara Current treatments for social anxiety disorder in adolescents: A narrative review
Jung et al. Effects of lidocaine, ketamine, and remifentanil on withdrawal response of rocuronium
BR112023026160A2 (pt) Valbenazina para uso no tratamento de discinesia devido à paralisia cerebral
BR112023021151A2 (pt) Métodos para administração de certos inibidores de vmat2
BR112021016913A2 (pt) Método para tratar doenças relacionadas a tnfa
MX2022014586A (es) Métodos y composiciones para tratar la fuga vascular.
BR112022003126A2 (pt) Conjugado terapêutico
Ivani et al. 1,000 consecutive blocks in a children's hospital: How to manage them safely
Ravi et al. Surgical anaesthesia for scapular surgery in a patient with ipsilateral thoracic injury
Chen et al. Three-year community case management for early psychosis: a randomised controlled study
Cho et al. Anaphylaxis induced by priming dose of rocuronium during induction of anesthesia: Report of two cases